Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma

Background: Primary resistance to immunotherapy can be observed in approximately 40–65% of the stage IV melanoma patients treated with immune checkpoint inhibitors. A minority of the patients receive a second-line therapy, and the clinical benefit is small. Patients and methods: Stage IV melanoma pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaral, Teresa, Seeber, Olivia, Mersi, Edgar, Sanchez, Stephanie, Thomas, Ioannis, Meiwes, Andreas, Forschner, Andrea, Leiter, Ulrike, Eigentler, Thomas, Keim, Ulrike, Garbe, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226601/
https://www.ncbi.nlm.nih.gov/pubmed/32331243
http://dx.doi.org/10.3390/cancers12041027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226601/
https://www.ncbi.nlm.nih.gov/pubmed/32331243
http://dx.doi.org/10.3390/cancers12041027

Ejemplares similares